ArticleBrain communications2023
Harnessing cognitive trajectory clusterings to examine subclinical decline risk factors.
Article in Brain communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Blood-Based Tau as a Biomarker for Early Detection and Monitoring of Alzheimer's Disease: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Can Psychiatric Genetics Advance Without Incorporating a Life Course Perspective?Biological psychiatry · 2026Review
- Risk Factors and Annual Rates of Cognitive Decline in Elderly Mild Cognitive Impairment: A Retrospective Cohort Study.Neuropsychiatric disease and treatment · 2026Article
- Tau mediates the impact of amyloid and vascular disease burden on the trajectory of clinical symptoms.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Abnormal Amyloid-β Duration, Tau, and Neurodegeneration in Cranial Images.JAMA network open · 2025Article
- Voxel-wise insights into early Alzheimer's disease pathology progression: the association with APOE and memory decline.GeroScience · 2025Article
- APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-β.Brain : a journal of neurology · 2025Article
- Predictive Models for the Transition from Mild Neurocognitive Disorder to Major Neurocognitive Disorder: Insights from Clinical, Demographic, and Neuropsychological Data.Biomedicines · 2024Article
- Late-midlife lifestyle and brain and cognitive changes in individuals on the AD versus non-AD continuum.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Amyloid is associated with accelerated atrophy in cognitively unimpaired individuals.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive decline in Alzheimer's disease and other dementias typically begins long before clinical impairment. Identifying people experiencing subclinical decline may facilitate earlier intervention. This study developed cognitive trajectory clusters using longitudinally based random slope and change point parameter estimates from a Preclinical Alzheimer's disease Cognitive Composite and examined how baseline and most recently available clinical/health-related characteristics, cognitive statuses and biomarkers for Alzheimer's disease and vascular disease varied across these cognitive clusters. Data were drawn from the Wisconsin Registry for Alzheimer's Prevention, a longitudinal cohort study of adults from late midlife, enriched for a parental history of Alzheimer's disease and without dementia at baseline. Participants who were cognitively unimpaired at the baseline visit with ≥3 cognitive visits were included in trajectory modelling (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.